MedTrace Logo

Caudal Dexmetedomedine Versus Magnesium in Orthopedic Pediatric Surgeries

NCT03460041 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2018-03-09

No results posted yet for this study

Summary

This study will be performed in Abo Elreesh Pediatric Hospital / Cairo University after obtaining approval by the University Ethics Committee, and a written informed consent from the parents or guardians.

Thirty six patients will be randomly assigned using an online randomization program (http://www.randomizer.org) and the sealed envelope method into three groups: Group D (n=12): Dexmetedomidine group. 0.5 ml of dexmetedomidine (2 μg/kg) added to bupivacaine, Group M (n=12) : Magnesium group.0.5 ml of magnesium sulphate (50 mg) added to bupivacaine, Group C (n=12) :Control group.bupivacaine 0.25% diluted in normal saline with total volume of 1 ml/kg.

Conditions

  • Pain in Pediatric Patients

Interventions

DRUG

Magnesium Sulfate

caudal magnesium sulphate added to bupivacaine for pain management

DRUG

Dexmetedomedine

Caudal dexmetedomedine added to bupivacaine for pain management

DRUG

Bupivacaine

Caudal bupivacaine for pain management

Sponsors & Collaborators

  • Cairo University

    collaborator OTHER

  • Hagar hassanein refaee

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
1 Year
Max Age
7 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-12-01
Primary Completion
2018-03-15
Completion
2018-03-15

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03460041 on ClinicalTrials.gov